Datapoint: AbbVie and Alvotech Settle Humira Dispute

AbbVie and Alvotech have settled their patent and trade secret disputes, ending a years-long legal battle over Alvotech’s Humira biosimilar. The drug, which Alvotech says has potential as an interchangeable biosimilar, could now launch as early as July 2023 pending FDA review, and Alvotech will pay licensing royalties to AbbVie. For the treatment of psoriasis, Humira holds preferred status for 64% of all insured lives. Virtually all covered lives have some form of access to Humira.

SOURCE: MMIT Analytics, as of 3/14/22

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 11

Datapoint: Kansas Rejects Medicaid Contract Challenges

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 10

Datapoint: FDA Approves Sandoz, Samsung Bioepis’ Stelara Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 9

Datapoint: FDA Approves Lilly’s New Alzheimer’s Drug

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today